8 results on '"Barnhart, Todd E."'
Search Results
2. ImmunoPET imaging of CD38 in murine lymphoma models using 89Zr-labeled daratumumab.
- Author
-
Kang, Lei, Jiang, Dawei, England, Christopher G., Barnhart, Todd E., Yu, Bo, Rosenkrans, Zachary T., Wang, Rongfu, Engle, Jonathan W., Xu, Xiaojie, Huang, Peng, and Cai, Weibo
- Subjects
POSITRON emission tomography ,BCL-2 proteins ,CD38 antigen ,HEMATOLOGICAL oncology ,CANCER - Abstract
Purpose: CD38 is considered a potential biomarker for multiple myeloma (MM) and has shown a strong link with chronic lymphocytic leukemia due to high and uniform expression on plasma cells. In vivo evaluation of CD38 expression may provide useful information about lesion detection and prognosis of treatment in MM. In this study, immunoPET imaging with
89 Zr-labeled daratumumab was used for differentiation of CD38 expression in murine lymphoma models to provide a potential non-invasive method for monitoring CD38 in the clinic.Methods: Daratumumab was radiolabeled with89 Zr (t1/2 = 78.4 h) via conjugation with desferrioxamine (Df). After Western blot (WB) was used to screen CD38 expression in five lymphoma cell lines, flow cytometry and cellular binding assays were performed to test the binding ability of labeled or conjugated daratumumab with CD38 in vitro. PET imaging and biodistribution studies were performed to evaluate CD38 expression after injection of89 Zr-Df-daratumumab.89 Zr-Df-IgG was also evaluated as a non-specific control group in the Ramos model. Finally, CD38 expression in tumor tissues was verified by histological analysis.Results: Using WB screening, the Ramos cell line was found to express the highest level of CD38 while the HBL-1 cell line had the lowest expression. Df-conjugated and89 Zr-labeled daratumumab displayed similar high binding affinities with Ramos cells. PET imaging of89 Zr-Df-daratumumab showed a high tumor uptake of up to 26.6 ± 8.0 %ID/g for Ramos at 120 h post-injection, and only up to 6.6 ± 2.9 %ID/g for HBL-1 (n = 4). Additionally,89 Zr-Df-IgG demonstrated a low tumor uptake in the Ramos model (only 4.3 ± 0.8 %ID/g at 120 h post-injection). Ex vivo biodistribution studies showed similar trends with imaging results. Immunofluorescence staining of tumor tissues verified higher CD38 expression of Ramos than that of HBL-1.Conclusions: The role of89 Zr-Df-daratumumab was investigated for evaluating CD38 expression in lymphoma models non-invasively and was found to be to a promising imaging agent of CD38-positive hematological diseases such as MM in future clinical applications. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
3. Hollow mesoporous silica nanoparticles for tumor vasculature targeting and PET image-guided drug delivery.
- Author
-
Chakravarty, Rubel, Goel, Shreya, Hong, Hao, Chen, Feng, Valdovinos, Hector F, Hernandez, Reinier, Barnhart, Todd E, and Cai, Weibo
- Abstract
Aim: Development of multifunctional and well-dispersed hollow mesoporous silica nanoparticles (HMSNs) for tumor vasculature targeted drug delivery and PET imaging. Materials & methods: Amine functionalized HMSNs (150-250 nm) were conjugated with a macrocyclic chelator, (S)-2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triaceticacid (NOTA), PEGylated and loaded with antiangiogenesis drug, Sunitinib. Cyclo(Arg-Gly-Asp-D-Tyr-Lys) (cRGDyK) peptide was attached to the nanoconjugate and radiolabeled with
64 Cu for PET imaging. Results:64 Cu-NOTA-HMSN-PEG-cRGDyK exhibited integrin-specific uptake both in vitro and in vivo. PET results indicated approximately 8% ID/g uptake of targeted nanoconjugates in U87MG tumors, which correlated well with ex vivo and histological analyses. Enhanced tumor-targeted delivery of sunitinib was also observed. Conclusion: We successfully developed tumor vasculature targeted HMSNs for PET imaging and image-guided drug delivery. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
4. Deficient Import of Acetyl-CoA into the ER Lumen Causes Neurodegeneration and Propensity to Infections, Inflammation, and Cancer.
- Author
-
Yajing Peng, Mi Li, Clarkson, Ben D., Pehar, Mariana, Lao, Patrick J., Hillmer, Ansel T., Barnhart, Todd E., Christian, Bradley T., Mitchell, Heather A., Bendlin, Barbara B., Sandor, Matyas, and Puglielli, Luigi
- Subjects
NEURODEGENERATION ,ACETYLCOENZYME A ,ENDOPLASMIC reticulum ,GENETIC mutation ,INFLAMMATION ,CANCER - Abstract
The import of acetyl-CoA into the ER lumen by AT-1/SLC33A1 is essential for the N
ε -lysine acetylation of ER-resident and ER-transiting proteins. A point-mutation (S113R) in AT-1 has been associated with a familial form of spastic paraplegia. Here, we report that AT-1S113R is unable to form homodimers in the ER membrane and is devoid of acetyl-CoA transport activity. The reduced influx of acetyl-CoA into the ER lumen results in reduced acetylation of ER proteins and an aberrant form of autophagy. Mice homozygous for the mutation display early developmental arrest. In contrast, heterozygous animals develop to full term, but display neurodegeneration and propensity to infections, inflammation, and cancer. The immune and cancer phenotypes are contingent on the presence of pathogens in the colony, whereas the nervous system phenotype is not. In conclusion, our results reveal a previously unknown aspect of acetyl-CoA metabolism that affects the immune and nervous systems and the risk for malignancies. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
5. Chelator-Free Synthesis of a Dual-Modality PET/MRI Agent.
- Author
-
Chen, Feng, Ellison, Paul A., Lewis, Christina M., Hong, Hao, Zhang, Yin, Shi, Sixiang, Hernandez, Reinier, Meyerand, M. Elizabeth, Barnhart, Todd E., and Cai, Weibo
- Subjects
IRON chelate synthesis ,CHELATES ,POSITRON emission tomography ,MAGNETIC resonance imaging ,ARSENIC compound synthesis - Abstract
Old technique, new application: A simple and efficient chelator‐free strategy for the synthesis of a novel dual‐modality PET/MRI agent has been developed. Labeling of radioarsenic (*AsIII and *AsV, *=71, 72, 74, 76) at the surface of superparamagnetic iron oxide nanoparticles (SPIONs) resulted in *As‐SPIONs that can be used for simultaneous PET/MRI in cancer diagnosis, lymph‐node mapping, and potentially for internal radiotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
6. Bacteria-like mesoporous silica-coated gold nanorods for positron emission tomography and photoacoustic imaging-guided chemo-photothermal combined therapy.
- Author
-
Xu, Cheng, Chen, Feng, Valdovinos, Hector F., Jiang, Dawei, Goel, Shreya, Yu, Bo, Sun, Haiyan, Barnhart, Todd E., Moon, James J., and Cai, Weibo
- Subjects
- *
MESOPOROUS silica , *DRUG delivery devices , *CANCER treatment , *NANOMEDICINE , *COMBINATION drug therapy , *PHOTOTHERAPY - Abstract
Mesoporous silica nanoshell (MSN) coating has been demonstrated as a versatile surface modification strategy for various kinds of inorganic functional nanoparticles, such as gold nanorods (GNRs), to achieve not only improved nanoparticle stability but also concomitant drug loading capability. However, limited drug loading capacity and low tumor accumulation rate in vivo are two major challenges for the biomedical applications of MSN-coated GNRs (GNR@MSN). In this study, by coating uniformly sized GNRs with MSN in an oil-water biphase reaction system, we have successfully synthesized a new bacteria-like GNR@MSN (i.e., bGNR@MSN) with a significantly enlarged pore size (4–8 nm) and surface area (470 m 2 /g). After PEGylation and highly efficient loading of doxorubicin (DOX, 40.9%, w/w), bGNR@MSN were used for positron emission tomography (PET, via facile and chelator-free 89 Zr-labeling) and photoacoustic imaging-guided chemo-photothermal cancer therapy in vivo . PET imaging showed that 89 Zr-labeled bGNR@MSN(DOX)-PEG can passively target to the 4T1 murine breast cancer-bearing mice with high efficiency (∼10 %ID/g), based on enhanced permeability and retention effect. Significantly enhanced chemo-photothermal combination therapy was also achieved due to excellent photothermal effect and near-infrared-light-triggered drug release by bGNR@MSN(DOX)-PEG at the tumor site. The promising results indicate great potential of bGNR@MSN-PEG nanoplatforms for future cancer diagnosis and therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
7. Tumor vasculature targeting and imaging in living mice with reduced graphene oxide
- Author
-
Shi, Sixiang, Yang, Kai, Hong, Hao, Valdovinos, Hector F., Nayak, Tapas R., Zhang, Yin, Theuer, Charles P., Barnhart, Todd E., Liu, Zhuang, and Cai, Weibo
- Subjects
- *
TUMOR treatment , *BLOOD vessels , *TARGETED drug delivery , *LABORATORY mice , *GRAPHENE , *NANOSTRUCTURED materials , *POSITRON emission tomography - Abstract
Abstract: Graphene-based nanomaterials have attracted tremendous attention in the field of biomedicine due to their intriguing properties. Herein, we report tumor vasculature targeting and imaging in living mice using reduced graphene oxide (RGO), which was conjugated to the anti-CD105 antibody TRC105. The RGO conjugate, 64Cu–NOTA–RGO–TRC105, exhibited excellent stability in vitro and in vivo. Serial positron emission tomography (PET) imaging studies non-invasively assessed the pharmacokinetics and demonstrated specific targeting of 64Cu–NOTA–RGO–TRC105 to 4T1 murine breast tumors in vivo, compared to non-targeted RGO conjugate (64Cu–NOTA–RGO). In vivo (e.g., blocking 4T1 tumor uptake with excess TRC105), in vitro (e.g., flow cytometry), and ex vivo (e.g., histology) experiments confirmed the specificity of 64Cu–NOTA–RGO–TRC105 for tumor vascular CD105. Since RGO exhibits desirable properties for photothermal therapy, the tumor-specific RGO conjugate developed in this work may serve as a promising theranostic agent that integrates imaging and therapeutic components. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
8. HPMA-based star polymer biomaterials with tuneable structure and biodegradability tailored for advanced drug delivery to solid tumours.
- Author
-
Kostka, Libor, Kotrchová, Lenka, Šubr, Vladimír, Libánská, Alena, Ferreira, Carolina A., Malátová, Iva, Lee, Hye Jin, Barnhart, Todd E., Engle, Jonathan W., Cai, Weibo, Šírová, Milada, and Etrych, Tomáš
- Subjects
- *
STAR-branched polymers , *MOLECULAR weights , *ACRYLAMIDE , *BIOMATERIALS , *PROPIONIC acid , *TUMORS , *COPOLYMERS - Abstract
Design, controlled synthesis, physico-chemical and biological characteristics of novel well-defined biodegradable star-shaped copolymers intended for advanced drug delivery is described. These new biocompatible star copolymers were synthesised by grafting monodispersed semitelechelic linear (sL) N -(2-hydroxypropyl)methacrylamide copolymers onto a 2,2-bis(hydroxymethyl)propionic acid (bisMPA)-based polyester dendritic core of various structures. The hydrodynamic diameter of the star copolymer biomaterials can be tuned from 13 to 31 nm and could be adjusted to a given purpose by proper selection of the bisMPA dendritic core type and generation and by considering the sL copolymer molecular weight and polymer-to-core molar ratio. The hydrolytic degradation was proved for both the star copolymers containing either dendron or dendrimer core, showing the spontaneous hydrolysis in duration of few weeks. Finally, it was shown that the therapy with the biodegradable star conjugate with attached doxorubicin strongly suppresses the tumour growth in mice and is fully curative in most of the treated animals at dose corresponding approximately to one fourth of maximum tolerated dose (MTD) value. Both new biodegradable systems show superior efficacy and tumour accumulation over the first generation of star copolymers containing non-degradable PAMAM core. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.